SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled

[May 07, 2014]

Research and Markets: Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/shrt7g/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.


Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Involved:

  • AEterna Zentaris Inc.
  • Acceleron Pharma, Inc.
  • ArQule, Inc.
  • Ariad Pharmaceuticals, Inc.
  • Arno Therapeutics, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Critical Outcome Technologies Inc.
  • Eisai Co., Ltd.
  • Esperance Pharmaceuticals, Inc.
  • Exelixis, Inc.
  • Galena Biopharma, Inc.
  • GlaxoSmithKline plc
  • Igenica, Inc.
  • ImmunoGen, Inc.
  • Ipsen S.A.
  • Merck & Co., Inc.
  • Novartis AG
  • OncoHoldings, Inc.
  • Oryzon Genomics S.A.
  • Pfizer Inc.
  • Pharmsynthez
  • Scancell Holdings Plc
  • Taiho Pharmaceutical Co., Ltd.

Drug Profiles:

  • zoptarelin doxorubicin
  • ixabepilone
  • lenvatinib
  • MK-2206
  • PF-05212384
  • ridaforolimus
  • dalantercept
  • cabozantinib (s)-malate
  • nintedanib
  • EP-100
  • dovitinib lactate
  • buparlisib hydrochloride
  • Virexxa
  • GALE-301
  • GSK-2636771
  • GSK-2141795
  • GSK-2256098
  • GSK-2141795 + trametinib
  • IMGN-853
  • ARQ-092
  • onapristone ER
  • COTI-2
  • EP-200
  • ONCO-101
  • TAS-2985
  • SERD 2
  • (ponatinib + ridaforolimus)
  • Virexxa
  • Monoclonal Antibody For Endometrial Cancer
  • Small Molecules for Oncology and Infectious Disease

For more information visit http://www.researchandmarkets.com/research/shrt7g/endometria


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy